Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.

Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.

Bibliografske podrobnosti
Main Authors:	Plata-Munoz, J, Vaidya, A, Fuggle, S, Friend, P
Format:	Journal article
Jezik:	English
Izdano:	2009

Podobne knjige/članki

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
od: Haynes, R, et al.
Izdano: (2014)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
od: Haynes, R, et al.
Izdano: (2014)

Impact of monoclonal antibody based-induction therapy on postoperative graft function and survival of kidneys from non-heart-beating donors.
od: Plata-Munoz, J, et al.
Izdano: (2007)

The deceased donor score system in kidney transplants from deceased donors after cardiac death.
od: Plata-Munoz, J, et al.
Izdano: (2010)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
od: Haynes, R, et al.
Izdano: (2014)

Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction
od: Annemarie Weissenbacher, et al.
Izdano: (2015-01-01)

Impact of pulsatile perfusion on postoperative outcome of kidneys from controlled donors after cardiac death.
od: Plata-Munoz, J, et al.
Izdano: (2008)

Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
od: Masashi Furukawa, et al.
Izdano: (2022-06-01)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
od: Muthusamy, A, et al.
Izdano: (2011)

Alemtuzumab induction and steroid free immunosupprssion in pancreas transplantation.
od: Muthusamy, A, et al.
Izdano: (2007)

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
od: Muthusamy, A, et al.
Izdano: (2008)

Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab
od: Ricardo Wang, et al.
Izdano: (2015-01-01)

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
od: Muthusamy, A, et al.
Izdano: (2007)

Central role of pulsatile perfusion on preservation of kidneys from controlled non-heart-beating donors.
od: Plata-Munoz, J, et al.
Izdano: (2007)

Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation
od: Himanshu V Patel, et al.
Izdano: (2014-01-01)

Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis
od: David Ansari, et al.
Izdano: (2016-01-01)

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
od: Martina Koch, et al.
Izdano: (2009-01-01)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
od: Watson, C, et al.
Izdano: (2005)

Outcomes of thymoglobulin versus basiliximab induction therapies in living donor kidney transplant recipients with mild to moderate immunological risk – a retrospective analysis of UNOS database
od: Hatem Ali, et al.
Izdano: (2023-12-01)

Survival Benefit of Kidney Transplantation from Donors after Cardiac Death.
od: Snoeijs, MG, et al.
Izdano: (2009)

Kidneys from donors after cardiac death provide survival benefit.
od: Snoeijs, MG, et al.
Izdano: (2010)

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
od: Morgan, R, et al.
Izdano: (2012)

The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
od: Su Yeon Hong, et al.
Izdano: (2023-01-01)

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
od: Flechner, S, et al.
Izdano: (2005)

The deceased donor score system as tool to guide preservation strategies before organ recovery and HLA-match
od: Plata-Munoz, J, et al.
Izdano: (2008)

Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation
od: Brook, MO, et al.
Izdano: (2024)

In response to: Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.
od: Knight, SR, et al.
Izdano: (2008)

Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study
od: Ngan N. Lam, MD, et al.
Izdano: (2021-08-01)

Alemtuzumab: right drug, right dose?
od: Haynes, R, et al.
Izdano: (2011)

Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial
od: Aziza Ajlan, et al.
Izdano: (2021-06-01)

Pancreas transplantation from donors after circulatory death from the United Kingdom.
od: Muthusamy, A, et al.
Izdano: (2012)

Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry
od: Jun Young Lee, et al.
Izdano: (2022-09-01)

POS-744 CLINICAL CORRELATES AND OUTCOMES OF DUAL BASILIXIMAB AND THYMOGLOBULIN INDUCTION IN KIDNEY TRANSPLANT RECIPIENTS: A NATIONAL STUDY
od: N. Lam N, et al.
Izdano: (2021-04-01)

Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
od: Sutherland, A, et al.
Izdano: (2014)

¿Which peritransplant features can predict graft survival in donor after circulatory death kidney transplantation?
od: Iris Coello, et al.
Izdano: (2023-07-01)

Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation
od: Xin-Ya Jiang, et al.
Izdano: (2024-06-01)

KIDNEY TRANSPLANTATION FROM DONORS AFTER CARDIAC DEATH
od: R.L. Rozental, et al.
Izdano: (2012-03-01)

Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients
od: Martina Guthoff, et al.
Izdano: (2020-05-01)

The impact of Recipient and Donor Characteristics on Kidney Transplant Graft Survival
od: Azza A I. Elmenyawia, et al.
Izdano: (2021-01-01)

Fatal anaphylactic reaction due to Basiliximab
od: Patricia Lovisolo, et al.
Izdano: (2017-04-01)